EMMAC Life Sciences Group has completed the first step to having its CBD brands fully authorised by the European Food Safety Authority (EFSA).
Since 2019, products containing CBD have been designated as novel foods in the EU, a move which means producers must demonstrate their products are safe for human consumption to remain on shelves.
The UK adopted the EU’s regulations on CBD when it left the bloc and is conducting its own novel food application process. EMMAC is yet to received validation in the UK.
Products produced by the company use a synthetic form of CBD which isn’t derived from the cannabis plant and therefore not subject to the same strict legal controls.
The firm partnered with Farmabios, a member of the PharmaZell Group, to formulate a nature-identical, pure CBD alternative with undetectable THC levels.
Commenting on the validation, EMMAC CEO Antonio Costanzo, said: “The European Commission’s decision on CBD is crucial to protecting European consumers and EMMAC welcomes its efforts to regulate the sector with meaningful regulation that ensures the safety of CBD products.
“As always, EMMAC takes a science-led approach to deliver the highest-quality products possible and we are delighted that this has led to being one of the first companies in Europe to receive validation for CBD.”
American cannabis giants Curaleaf – which generated $600million in revenue in 2020 – took over EMMAC earlier this year in a $285million move.